Treatment and Daily Management of NEDSGO
At a Glance
NEDSGO care is tailored to each child: a neurologist should review seizure treatment, daily oral hygiene and dental monitoring help control gum problems, and therapies support movement, communication, feeding, and independence.
Because NEDSGO is an ultra-rare condition, there is no single “standard” treatment protocol that fits every child. Instead, doctors use a phenotype-driven approach, which means they tailor your child’s care plan to the specific symptoms they are showing [1][2]. This approach focuses on managing seizures, supporting development, and maintaining oral health through a collaborative, multidisciplinary team [3].
Managing Seizures and the Phenytoin Caution
Seizures affect approximately 8 of 10 reported individuals with NEDSGO and are a primary focus of medical care [4]. Your neurologist will likely use EEGs to monitor brain activity and determine the best anti-seizure medications (ASMs) [5].
A critical consideration in NEDSGO is the interaction between seizure medications and gum health.
- The Phenytoin Issue: Phenytoin is a common seizure medication known to cause or worsen gingival enlargement (gum overgrowth) in about 50% of the people who take it [6][7]. In children who already have NEDSGO-related genetic gum growth, phenytoin can make the tissue thicker and more fibrotic, which makes oral hygiene harder and can interfere with eating and speaking [8][9].
- Medication Review: If your child is prescribed phenytoin, it is important to discuss alternatives with your neurologist. While no medication is entirely risk-free, drugs like valproate or carbamazepine may have lower reported rates of gum enlargement in some studies [10][11], though they must still be balanced carefully against their effectiveness for your child’s specific seizure type and their own unique risks. Never stop or change a seizure medication without medical supervision, as sudden changes can cause severe breakthrough seizures [6].
Oral Health and Gingival Care
Managing the “gingival overgrowth” (GO) part of NEDSGO is a long-term process. The overgrowth is genetic, meaning brushing will not cure it, but rigorous hygiene is necessary to keep the mouth healthy and ensure your child can eat, speak, and breathe comfortably.
- Nonsurgical Management: The first line of defense is rigorous plaque control. Excess gum tissue creates “pockets” where bacteria (plaque) can hide, causing secondary inflammation that triggers even more swelling [8]. Daily caregiver-assisted brushing and professional cleanings—often tailored to the individual’s needs, such as every three months—are essential to reduce this inflammation [12][9].
- Surgical Options: If the soft gum tissue becomes so thick that it covers the teeth, makes chewing painful, or blocks the airway, a procedure called a gingivectomy may be necessary [13]. This is the surgical removal of excess gum tissue. While this can provide significant relief, it is important to know that the tissue may grow back (recurrence) over time, requiring ongoing monitoring [14][15]. Any dental surgery also requires careful perioperative airway and anesthesia planning coordinated with neurology.
- Monitoring the Jaw: Beyond the gums, some children develop fibrous dysplasia, where the bone in the jaw is replaced by fibrous tissue [4]. Your care team may use periodic imaging based on symptoms to ensure this bone growth is not pressing on vital structures or obstructing breathing [16].
Daily Developmental Therapies
Supporting your child’s growth and independence requires a combination of specialized therapies. These are most effective when started early and adjusted as your child grows:
- Physical Therapy (PT): Focuses on gross motor skills, such as balance, walking stability, and managing the tremors or unsteadiness (ataxia) that some children with NEDSGO develop [16][17].
- Occupational Therapy (OT): Helps with fine motor skills (like grasping objects) and “activities of daily living,” such as feeding themselves or dressing [18][19].
- Speech and Feeding Therapy: Because gum overgrowth and jaw changes can affect the mouth’s movement, speech therapy is vital. These specialists also assess dysphagia (swallowing difficulties) and can recommend augmentative and alternative communication (AAC) tools, such as picture boards or speech-generating devices, if your child’s verbal speech is limited [20][21].
Coordinating Your Care Team
Since NEDSGO affects so many parts of the body, coordination is key. You may find it helpful to designate a “lead” doctor (often the neurologist or a complex care pediatrician) who can help share information between the dentist, therapists, and other specialists [18][22]. Using tools like Goal-Attainment Scaling—where you and your therapists set specific, measurable goals for your child—can help ensure that everyone is working toward the same priorities for your family [19].
Common questions in this guide
Could phenytoin make my child’s NEDSGO gum overgrowth worse?
How can we care for my child’s gums every day?
When is gum surgery considered for a child with NEDSGO?
What therapies can help my child’s development and independence?
How often should my child see the dental team?
How can we coordinate the specialists caring for a child with NEDSGO?
Get notified when new evidence is published on neurodevelopmental disorder with seizures and gingival overgrowth.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (22)
- 1
Biallelic loss-of-function variants in TBC1D2B cause a neurodevelopmental disorder with seizures and gingival overgrowth.
Harms FL, Parthasarathy P, Zorndt D, et al.
Human mutation 2020; (41(9)):1645-1661 doi:10.1002/humu.24071.
PMID: 32623794 - 2
CDK13-related disorder.
Hamilton MJ, Suri M
Advances in genetics 2019; (103()):163-182 doi:10.1016/bs.adgen.2018.11.001.
PMID: 30904094 - 3
Beyond seizures: the hidden burden of developmental epileptic encephalopathies.
Dell'Isola GB, Sorrentino M, Massara S, et al.
Frontiers in neurology 2026; (17()):1960314 doi:10.3389/fneur.2026.1960314.
PMID: 42953089 - 4
Loss of TBC1D2B causes a progressive neurological disorder with gingival overgrowth.
Harms FL, Rexach JE, Efthymiou S, et al.
European journal of human genetics : EJHG 2024; (32(5)):558-566 doi:10.1038/s41431-024-01563-5.
PMID: 38374468 - 5
A Novel Homozygous TBC1D2B Variant Disrupts Functional Domains and Suggests Impaired Rab-GTPase Regulation in Neurodevelopmental Disorder.
Ozturk M, Arslan CB, Akbulut E, et al.
Developmental neurobiology 2025; (85(4)):e22998 doi:10.1002/dneu.22998.
PMID: 40898781 - 6
Risk Factors and Management of Gingival Enlargement: A Systematic Review and Meta-Analysis.
Nibali L, Lu EM, Paz HES, et al.
Journal of clinical periodontology 2026; doi:10.1111/jcpe.70125.
PMID: 42260319 - 7
TRPA1 Channels Mediate Human Gingival Fibroblast Response to Phenytoin.
López-González MJ, Luis E, Fajardo O, et al.
Journal of dental research 2017; (96(7)):832-839 doi:10.1177/0022034517695518.
PMID: 28571526 - 8
Successful Management of Generalized Drug-Influenced Gingival Enlargement: A Clinical Case Report.
Bansal R, Patle ND, Ratre MS, Khetarpal S
Cureus 2026; (18(9)):e116089 doi:10.7759/cureus.116089.
PMID: 42861111 - 9
Periodontal Management to Improve Oral Health-related Quality of Life in an Adolescent Girl with Phenytoin-induced Gingival Enlargement: A Case Report.
Dawar A, Gumber B, Makker K
International journal of clinical pediatric dentistry 2025; (18(5)):599-605 doi:10.5005/jp-journals-10005-3133.
PMID: 41050299 - 10
A Clinical Evaluation of Gingival Overgrowth in Children on Antiepileptic Drug Therapy.
Suneja B, Chopra S, Thomas AM, Pandian J
Journal of clinical and diagnostic research : JCDR 2016; (10(1)):ZC32-6 doi:10.7860/JCDR/2016/16443.7069.
PMID: 26894172 - 11
Gingival overgrowth induced by anticonvulsant drugs: A cross-sectional study on epileptic patients.
Gallo C, Bonvento G, Zagotto G, Mucignat-Caretta C
Journal of periodontal research 2021; (56(2)):363-369 doi:10.1111/jre.12828.
PMID: 33368283 - 12
Initial periodontal therapy for seven patients with aplastic anemia and drug-induced gingival overgrowth: a case series report.
Lv X, Yang X, Lv X, et al.
BMC oral health 2025; (25(1)):847 doi:10.1186/s12903-025-06211-y.
PMID: 40442749 - 13
Gingival overgrowth: Part 2: management strategies.
Chesterman J, Beaumont J, Kellett M, Durey K
British dental journal 2017; (222(3)):159-165 doi:10.1038/sj.bdj.2017.111.
PMID: 28184072 - 14
Nonsyndromic with Recurrent Idiopathic Gingival Fibromatosis: A Rare Case Report.
Kumari A, Bansal MB, Asrani KH, Yadav A
International journal of clinical pediatric dentistry 2021; (14(1)):158-160 doi:10.5005/jp-journals-10005-1933.
PMID: 34326603 - 15
Management of periodontal disease in patients using calcium channel blockers - gingival overgrowth, prescribed medications, treatment responses and added treatment costs.
Fardal Ø, Lygre H
Journal of clinical periodontology 2015; (42(7)):640-6 doi:10.1111/jcpe.12426.
PMID: 26076712 - 16
Biallelic frameshift variant in the TBC1D2B gene in two siblings with progressive gingival overgrowth, fibrous dysplasia of face, and mental deterioration.
Correia-Costa GR, de Leeuw N, Pfundt R, et al.
Clinical genetics 2022; (102(6)):537-542 doi:10.1111/cge.14215.
PMID: 36029130 - 17
Learnings in developmental and epileptic encephalopathies: what do we know?
Perinelli MG, Riva A, Amadori E, et al.
Expert review of neurotherapeutics 2023; (23(1)):45-57 doi:10.1080/14737175.2023.2176221.
PMID: 36726225 - 18
Needs of children with neurodevelopmental disorders and medical complexity: Caregiver perspectives.
Materula D, Currie G, Jia XY, et al.
Research in developmental disabilities 2024; (153()):104815 doi:10.1016/j.ridd.2024.104815.
PMID: 39142086 - 19
The Feasibility of Personalized Endpoints in Assessing Treatment Outcomes for Rare Diseases: A Pilot Study of Goal Attainment Scaling in SCN2A-Associated Developmental Epileptic Encephalopathy.
Sevinc G, Knox K, George M, et al.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2025; (28(3)):441-448 doi:10.1016/j.jval.2024.12.004.
PMID: 39733836 - 20
SYNGAP1-related developmental and epileptic encephalopathy: The impact on daily life.
Lo Barco T, De Gaetano L, Santangelo E, et al.
Epilepsy & behavior : E&B 2022; (127()):108500 doi:10.1016/j.yebeh.2021.108500.
PMID: 34954508 - 21
Understanding lived experiences with KCNQ2 developmental and epileptic encephalopathy.
Potashman MH, Rudell K, Abetz-Webb L, et al.
Epilepsy & behavior : E&B 2025; (172()):110670 doi:10.1016/j.yebeh.2025.110670.
PMID: 40912075 - 22
Exploring Parents' Values in Healthcare Decision-Making for Rare Genetic Neurodevelopmental Disorders: A Qualitative Study to Inform Guideline Development.
Klein Haneveld MJ, Cox L, Embregts PJCM, et al.
Journal of intellectual disability research : JIDR 2026; (70(9)):913-922 doi:10.1111/jir.70150.
PMID: 42571921
This page provides educational information about managing NEDSGO and does not replace medical advice. Your child’s neurologist, dentist, and therapy team should guide medication changes, dental surgery, and individualized care.